ONCOS-102, Keytruda Combo May Reduce Tumor Size in Treatment-resistant Melanoma, Early Trial Data Show

Source: IMMUNO-ONCOLOGY NEWS, September 2019

Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest.

The trial is testing a combination of ONCOS-102 and the immune checkpoint inhibitor Keytruda (pembrolizumab) in advanced or surgery-ineligible melanoma patients whose tumor continued to progress despite treatment with an anti PD-1 antibody, such as Keytruda or Opdivo (nivolumab).

Early results showed that the combination reduced tumor size in three of the nine patients enrolled, including one patient whose disease completely disappeared.